Merck, GlaxoSmithKline won't provide copay help for ACA enrollees; Lessons every healthcare leader should know;

News From Around the Web

> Even with a rocky rollout, more than 6 million Americans have signed up on the health insurance exchanges since Oct. 1, the U.S. Department of Health & Human Services said yesterday. Announcement

> Merck and GlaxoSmithKline will hold off on subsidies for out-of-pocket drug costs to people insured under the Affordable Care Act, according to Marketwatch. Health plans and pharmacy benefit managers claim that when drug companies help with copay costs, it hurts their efforts to direct patients to lower-price generic medicines. Article

> Millennials, a key demographic for exchange success, aren't risk-takers, according to ThinkAdvisor. The survey of about 25,500, 27 percent of whom were 18 to 34 years old, found milliennails had only a 25 percent overall willingness to take on risk. Article

Healthcare Leadership News

> We currently deliver unreliable healthcare inconsistently at a very high cost; but with the ability to define and measure quality we can improve and drive down the total cost of care, Thomas Graf, M.D., chief medical officer for population health at Pennsylvania's Geisinger Health System, wrote in Hospital Impact. Blog Post

> Working within the ever-changing healthcare landscape requires healthcare leaders to dig deep and remember the important lessons learned from parents, former colleagues and bosses, wrote Darlene A. Cunha, R.N., a senior healthcare executive, in Hospital Impact. Blog Post

And Finally... I hope the final exam doesn't require twerking. Article

Suggested Articles

Insurance company Oscar hired former Uber talent as its chief executive officer, Jonathan Bush gets a new gig at Firefly Health and more.

Fourteen doctors and other medical professionals were among those charged in fraud cases that totaled $258 million in California, Oregon, and Arizona.

House Speaker Nancy Pelosi released a plan to give Medicare the power to negotiate for lower drug prices, but will it get out of Congress?